GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » ROA %

IMUC (EOM Pharmaceutical Holdings) ROA % : -27.31% (As of Jun. 2018)


View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. EOM Pharmaceutical Holdings's annualized Net Income for the quarter that ended in Jun. 2018 was $-1.23 Mil. EOM Pharmaceutical Holdings's average Total Assets over the quarter that ended in Jun. 2018 was $4.50 Mil. Therefore, EOM Pharmaceutical Holdings's annualized ROA % for the quarter that ended in Jun. 2018 was -27.31%.

The historical rank and industry rank for EOM Pharmaceutical Holdings's ROA % or its related term are showing as below:

IMUC's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -36.055
* Ranked among companies with meaningful ROA % only.

EOM Pharmaceutical Holdings ROA % Historical Data

The historical data trend for EOM Pharmaceutical Holdings's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings ROA % Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.45 -34.66 -46.29 -94.04 -119.77

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -211.62 -269.34 -25.01 -67.36 -27.31

Competitive Comparison of EOM Pharmaceutical Holdings's ROA %

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's ROA % distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's ROA % falls into.



EOM Pharmaceutical Holdings ROA % Calculation

EOM Pharmaceutical Holdings's annualized ROA % for the fiscal year that ended in Dec. 2017 is calculated as:

ROA %=Net Income (A: Dec. 2017 )/( (Total Assets (A: Dec. 2016 )+Total Assets (A: Dec. 2017 ))/ count )
=-14.312/( (16.89+7.009)/ 2 )
=-14.312/11.9495
=-119.77 %

EOM Pharmaceutical Holdings's annualized ROA % for the quarter that ended in Jun. 2018 is calculated as:

ROA %=Net Income (Q: Jun. 2018 )/( (Total Assets (Q: Mar. 2018 )+Total Assets (Q: Jun. 2018 ))/ count )
=-1.228/( (5.165+3.829)/ 2 )
=-1.228/4.497
=-27.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2018) net income data. ROA % is displayed in the 30-year financial page.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2018 )
=Net Income/Total Assets
=-1.228/4.497
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.228 / 0)*(0 / 4.497)
=Net Margin %*Asset Turnover
=N/A %*0
=-27.31 %

Note: The Net Income data used here is four times the quarterly (Jun. 2018) net income data. The Revenue data used here is four times the quarterly (Jun. 2018) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


EOM Pharmaceutical Holdings ROA % Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077